Physician profile
Temberly Long
NPI 1225406085
$1,042.94
in general payments reported to CMS, 2019-2025
15 companies · $53.20 in 2025
The $53.20 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $184 · 2023: $301 · 2024: $333 · 2025: $53.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $331.65 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $250.58 | 2022-2024 | |
| Lundbeck LLC | $156.90 | 2023-2025 | Rexulti |
| Insulet Corporation | $49.80 | 2023 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $49.06 | 2023-2024 | Breztri |
| Merck Sharp & Dohme LLC | $34.52 | 2022-2023 | Januvia, Belsomra |
| Teva Pharmaceuticals USA, INC. | $29.53 | 2021 | |
| Grifols USA, LLC | $22.78 | 2022 | |
| Boston Scientific Corporation | $18.49 | 2024 | |
| Novo Nordisk INC | $17.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.49 | 2024 | Trintellix |
| Dexcom, INC. | $17.15 | 2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $16.76 | 2022 | |
| Eisai INC. | $15.77 | 2021 | |
| Amgen INC. | $14.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Temberly Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.